CYTOKINETICS, INCORPORATED Paid-in-Kind Interest
CYTOKINETICS, INCORPORATED (CYTK) reported Paid-in-Kind Interest of $17.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-06
- CYTOKINETICS, INCORPORATED paid-in-kind interest for the quarter ending 2026-06-30 was $8.73M, a 63.81% increase year-over-year.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for the quarter ending 2026-03-31 was $8.46M, a 144.86% increase year-over-year.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for the quarter ending 2025-12-31 was $8.47M, a 139.81% increase year-over-year.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for the quarter ending 2025-09-30 was $5.65M, a 62.02% increase year-over-year.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for fiscal 2025 was $22.90M, a 98.12% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for fiscal 2024 was $11.56M, a 57.46% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for fiscal 2023 was $7.34M, a 28.86% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED paid-in-kind interest for fiscal 2022 was $5.70M, a 20.04% decline from fiscal 2021.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.19M 10-Q · filed 2026-08-06 | $25.66M derived: sum of 3 quarters · filed 2026-08-06 | $31.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $8.46M 10-Q · filed 2026-05-05 | $16.93M derived: sum of 2 quarters · filed 2026-05-05 | $22.57M derived: sum of 3 quarters · filed 2026-05-05 | $27.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.12M derived: sum of 2 quarters · filed 2026-02-26 | $19.45M derived: sum of 3 quarters · filed 2026-08-06 | $22.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $5.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $10.98M derived: sum of 2 quarters · filed 2026-08-06 | $14.43M 10-Q · filed 2025-11-05 | $17.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $8.78M 10-Q · filed 2026-08-06 | $12.31M derived: sum of 3 quarters · filed 2026-08-06 | $15.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.45M 10-Q · filed 2026-05-05 | $6.99M derived: sum of 2 quarters · filed 2026-05-05 | $10.47M derived: sum of 3 quarters · filed 2026-05-05 | $13.13M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $7.02M derived: sum of 2 quarters · filed 2026-02-26 | $9.68M derived: sum of 3 quarters · filed 2026-02-26 | $11.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $6.15M derived: sum of 2 quarters · filed 2025-11-05 | $8.03M 10-Q · filed 2025-11-05 | -$5.58M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.54M 10-Q · filed 2025-08-07 | -$9.07M derived: sum of 3 quarters · filed 2026-02-26 | -$1.99M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.88M 10-Q · filed 2025-05-06 | -$11.73M derived: sum of 2 quarters · filed 2026-02-26 | -$4.65M derived: sum of 3 quarters · filed 2026-02-26 | $2.33M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$13.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$6.53M derived: sum of 2 quarters · filed 2026-02-26 | $453.00K derived: sum of 3 quarters · filed 2026-02-26 | $7.34M 10-K · filed 2026-02-26 |
| 2023-09-30 | $7.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $14.06M derived: sum of 2 quarters · filed 2024-11-07 | $20.95M 10-Q · filed 2024-11-07 | $22.04M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $13.87M 10-Q · filed 2024-08-09 | $14.96M derived: sum of 3 quarters · filed 2025-02-27 | $16.93M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $6.89M 10-Q · filed 2024-05-10 | $7.98M derived: sum of 2 quarters · filed 2025-02-27 | $9.94M derived: sum of 3 quarters · filed 2025-02-27 | $11.29M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $3.06M derived: sum of 2 quarters · filed 2025-02-27 | $4.40M derived: sum of 3 quarters · filed 2025-02-27 | $5.70M 10-K · filed 2025-02-27 |
| 2022-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $3.31M derived: sum of 2 quarters · filed 2023-11-03 | $4.61M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $2.64M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $1.30M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $7.13M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $6.64M 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $919.00K 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $920.00K 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |